Benign Paroxysmal Positional Vertigo
Conditions
Interventions
Normal sleep group (based on baseline PSQI score, PSQI 7):N/A
Sponsors
Wuhan Hanyang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients must meet all of the following conditions to be eligible for inclusion:Age: 18 years <= Age <=75 years.Diagnosis: Meet the diagnostic criteria for idiopathic Benign Paroxysmal Positional Vertigo (BPPV) according to the Chinese Guideline for the Diagnosis and Treatment of Benign Paroxysmal Positional Vertigo (2017):A history of brief, episodic rotational vertigo provoked by changes in head position.Presence of vertigo and characteristic positional nystagmus during diagnostic positional tests (e.g., Dix-Hallpike test, Roll test).Other disorders have been ruled out, such as vestibular migraine, central positional vertigo, Ménière's disease, posterior circulation ischemia, and psychogenic dizziness.Treatment: Successful repositioning treatment administered via the SRM-IV BPPV Diagnosis and Treatment System. Success is defined as conversion of the provoking positional test to negative after 1 to 2 treatment sessions.Informed Consent: The patient fully understands the study content, voluntarily agrees to participate, and provides written informed consent.
Exclusion criteria
Exclusion criteria: Patients are excluded if they have any of the following conditions: Secondary BPPV: BPPV caused by a clear underlying cause (such as Ménière's disease, vestibular neuritis, head trauma, history of middle or inner ear surgery, sudden deafness with vertigo, etc.). Other vestibular or central nervous system diseases: combined with other active vestibular disorders (such as acute phase of confirmed Ménière's disease, vestibular migraine attacks, persistent position-perception dizziness, etc.). Presence of a clear central cause of vertigo or neurological disease (such as stroke, multiple sclerosis, intracranial tumor, etc.). Severe systemic diseases: severe, uncontrolled heart, lung, liver, or kidney dysfunction (based on biochemical indicators and clinical diagnosis). Confirmed autoimmune diseases, active malignant tumors, or hematologic disorders. Mental and cognitive disorders: severe mental disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (such as major depression, schizophrenia, bipolar disorder, etc.). Presence of obvious cognitive impairment, unable to understand the questionnaire or cooperate with the study procedures (such as a very low score on the Mini-Mental State Examination). Medication and substance use: long-term (within 2 weeks prior to the start of the study) regular use of medications that may significantly affect sleep, inflammation, or vestibular function, including but not limited to: glucocorticoids, immunosuppressants, sedative-hypnotic drugs, antipsychotic drugs, routine vestibular suppressants. History of drug or alcohol abuse. Special physiological conditions: women who are pregnant or breastfeeding. Abnormal laboratory tests: baseline blood routine tests indicating acute infection (such as significantly elevated white blood cell count with increased neutrophil proportion). Abnormal elevation of C-reactive protein (>10 mg/L), suggesting possible acute systemic inflammatory state.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pittsburgh Sleep Quality Index (PSQI);Recurrence;Position ;mRNA:TLR4, NLRP3 mRNA expression;Cytokine:NF-?B-RelAIL-1ß, IL-18, IL-6, TNF-a;Dizziness Handicap (DHI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Balance Function ;Residual Dizziness, RD; | — |
Countries
China
Contacts
Public ContactZhou Chunting
Wuhan Hanyang Hospital
Outcome results
None listed